Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Clinical trials of biologic agents for chronic active antibody-mediated rejection (CAMR) in kidney transplant recipients (KTRs) have been disappointing. We performed a clinical trial of mesenchymal stem cell (MSC) treatment in KTRs with CAMR unresponsive to rituximab and intravenous immunoglobulin....

Full description

Bibliographic Details
Main Authors:	Tae Hyun Ban, Sua Lee, Hyung Duk Kim, Eun Jeong Ko, Bo-Mi Kim, Kyoung-Woon Kim, Byung Ha Chung, Chul Woo Yang
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	Stem Cells International
Online Access:	http://dx.doi.org/10.1155/2021/6672644

Similar Items

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
by: Gun Hee An, et al.
Published: (2014-01-01)

Therapeutic Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection
by: Yaeni Kim, et al.
Published: (2014-06-01)

Use of Corticosteroid in Children with Unresponsiveness to Intravenous Immunoglobulin in Kawasaki Disease
by: Abdolkarim Hamedi, et al.
Published: (2017-08-01)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
by: A. Razzaque Ahmed, et al.
Published: (2018-07-01)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
by: Euri Seo, et al.
Published: (2016-10-01)

Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease
by: Ming-Tai Lin, et al.
Published: (2016-05-01)

Clinical significance of CD161+CD4+ T cells in the development of chronic antibody-mediated rejection in kidney transplant recipients.
by: Kyoung Woon Kim, et al.
Published: (2018-01-01)

Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
by: Gastón J Piñeiro, et al.
Published: (2018-10-01)

Impact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA.
by: Byung Ha Chung, et al.
Published: (2015-01-01)

Recipient natural killer cells alter the course of rejection of allogeneic heart grafts in rats.
by: Oliver Beetz, et al.
Published: (2019-01-01)

A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease
by: Yuji Amano, et al.
Published: (2019-07-01)

Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
by: Caroline Pilon, et al.
Published: (2020-01-01)

Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy
by: Stefania Leuci, et al.
Published: (2018-01-01)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
by: Knight T, et al.
Published: (2017-05-01)

INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION
by: A. I. Sushkov, et al.
Published: (2011-06-01)

Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction.
by: Byung Ha Chung, et al.
Published: (2015-01-01)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
by: Sung-Hoon Jung, et al.
Published: (2012-02-01)

Rituximab use in late antibody-mediated rejection
by: S B Bansal
Published: (2016-01-01)

Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
by: Marie Matignon, et al.
Published: (2017-01-01)

Salmonella Encephalopathy Treated with Early Use of Intravenous Immunoglobulin and Dexamethasone
by: Geon Hui Kim, et al.
Published: (2020-07-01)

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
by: Djamal Djeddi, et al.
Published: (2020-09-01)

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients
by: Marita Prohn, et al.
Published: (2021-03-01)

INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRICS
by: A.Yu. Shcherbina, et al.
Published: (2010-07-01)

Intravenous immunoglobulin in dermatology
by: Dhar Sandipan
Published: (2009-01-01)

INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRICS
by: A.Yu. Shcherbina, et al.
Published: (2010-01-01)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
by: Young Hoon Kim, et al.
Published: (2020-03-01)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
by: Veronica Di Cristanziano, et al.
Published: (2021-08-01)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
by: Hyung Suk Kim, et al.
Published: (2021-07-01)

Mesenchymal stem cells avoid allogeneic rejection
by: Murphy J Mary, et al.
Published: (2005-07-01)

Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants
by: Chih-Yuan Lee, et al.
Published: (2016-10-01)

Use of intravenous immunoglobulin in a disseminated varicella infection in an immunocompromised child
by: Jae Hong Kim, et al.
Published: (2014-08-01)

Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients
by: F Ahmadi, et al.
Published: (2019-07-01)

Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
by: Kasia A. Sablik, et al.
Published: (2019-06-01)

IMMUNOREGULATORY EFFECTS OF INTRAVENOUS IMMUNOGLOBULINS
by: S. A. Sel'kov, et al.
Published: (2014-07-01)

Intravenous Immunoglobulin Therapy in Myocarditis
by: Amir Hossein Mansourabadi, et al.
Published: (2020-08-01)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
by: Hyo Min Park, et al.
Published: (2013-02-01)

Immunosuppression and Rejection of Cartilage Formed by Allogeneic Chondrocytes in Rats
by: Anna Osiecka-Iwan, et al.
Published: (1999-11-01)

TRANCE/RANK in allogenic islet transplantation rejection response
by: Yi-Chun, Hsiao, et al.
Published: (2000)

Remission of Anti-laminin 332 Mucous Membrane Pemphigoid Associated with Non-small Cell Lung Cancer after Therapy with Rituximab and Intravenous Immunoglobulin
by: Evelyne Tarnowietzki, et al.
Published: (2020-10-01)

In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins.
by: Mehta Y, et al.
Published: (1996-04-01)